Real-world glycaemic outcomes in patients with type 1 diabetes using glucose sensors-Experience from a single centre in Dublin.
DAFNE
Dexcom G6
FreeStyle Libre
Guardian 3
continuous glucose monitor
flash glucose monitor
type 1 diabetes
Journal
Endocrinology, diabetes & metabolism
ISSN: 2398-9238
Titre abrégé: Endocrinol Diabetes Metab
Pays: England
ID NLM: 101732442
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
02
01
2024
received:
04
08
2023
accepted:
05
01
2024
medline:
25
1
2024
pubmed:
25
1
2024
entrez:
25
1
2024
Statut:
ppublish
Résumé
To evaluate changes in glycated haemoglobin (HbA We performed a retrospective observational single-centre study on HbA We observed an overall improvement in HbA Our study demonstrated that minimally invasive glucose sensor technology in adults with T1D is associated with improvement in glycaemic outcomes. However, despite significant improvements in HbA
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e469Informations de copyright
© 2024 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.
Références
Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741-760.
Committee ADAPP. 2. Classification and diagnosis of diabetes: standards of medical Care in Diabetes-2022. Diabetes Care. 2021;45(Supplement_1):S17-S38.
Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. The Lancet. 2014;383(9911):69-82.
Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.
Prigge R, McKnight JA, Wild SH, et al. International comparison of glycaemic control in people with type 1 diabetes: an update and extension. Diabet Med. 2022;39(5):e14766.
Vincze G, Barner JC, Lopez D. Factors associated with adherence to self-monitoring of blood glucose among persons with diabetes. Diabetes Educ. 2004;30(1):112-125.
Teo E, Hassan N, Tam W, Koh S. Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis. Diabetologia. 2022;65(4):604-619.
Lee K, Gunasinghe S, Chapman A, et al. Real-world outcomes of glucose sensor use in type 1 diabetes-findings from a large UK Centre. Biosensors (Basel). 2021;11(11):457.
Mulinacci G, Alonso GT, Snell-Bergeon JK, Shah VN. Glycemic outcomes with early initiation of continuous glucose monitoring system in recently diagnosed patients with type 1 diabetes. Diabetes Technol Ther. 2019;21(1):6-10.
Nathanson D, Svensson AM, Miftaraj M, Franzén S, Bolinder J, Eeg-Olofsson K. Effect of flash glucose monitoring in adults with type 1 diabetes: a nationwide, longitudinal observational study of 14,372 flash users compared with 7691 glucose sensor naive controls. Diabetologia. 2021;64(7):1595-1603.
Tyndall V, Stimson RH, Zammitt NN, et al. Marked improvement in HbA(1c) following commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia. 2019;62(8):1349-1356.
Deshmukh H, Wilmot EG, Gregory R, et al. Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide audit. Diabetes Care. 2020;43(9):2153-2160.
Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603.
Brown RE, Chu L, Norman GJ, Abitbol A. Real-world glycaemic outcomes in adult persons with type 1 diabetes using a real-time continuous glucose monitor compared to an intermittently scanned glucose monitor: a retrospective observational study from the Canadian LMC diabetes registry (REAL-CGM-T1D). Diabet Med. 2022;39(11):e14937.
Visser MM, Charleer S, Fieuws S, et al. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial. Lancet. 2021;397(10291):2275-2283.
Blauw H, Keith-Hynes P, Koops R, DeVries JH. A review of safety and design requirements of the artificial pancreas. Ann Biomed Eng. 2016;44(11):3158-3172.
Beck RW, Lawrence JM, Laffel L, et al. Quality-of-life measures in children and adults with type 1 diabetes: Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Care. 2010;33(10):2175-2177.
Jendle JH, Rawshani A, Svensson AM, Avdic T, Gudbjörnsdóttir S. Indications for insulin pump therapy in type 1 diabetes and associations with glycemic control. J Diabetes Sci Technol. 2016;10(5):1027-1033.
Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(7):501-512.
American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S73-s84.
Dovc K, Lanzinger S, Cardona-Hernandez R, et al. Association of achieving time in range clinical targets with treatment modality among youths with type 1 diabetes. JAMA Netw Open. 2023;6(2):e230077.
Silva JD, Lepore G, Battelino T, et al. Real-world performance of the MiniMed™ 780G system: first report of outcomes from 4120 users. Diabetes Technol Ther. 2022;24(2):113-119.
Pinsker JE, Müller L, Constantin A, et al. Real-world patient-reported outcomes and glycemic results with initiation of control-IQ technology. Diabetes Technol Ther. 2021;23(2):120-127.
Peacock S, Frizelle I, Hussain S. A systematic review of commercial hybrid closed-loop automated insulin delivery systems. Diabetes Ther. 2023;14(5):839-855.
Isganaitis E, Raghinaru D, Ambler-Osborn L, et al. Closed-loop insulin therapy improves glycemic control in adolescents and young adults: outcomes from the international diabetes closed-loop trial. Diabetes Technol Ther. 2021;23(5):342-349.
ElSayed NA, Aleppo G, Aroda VR, et al. 7. Diabetes technology: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S111-S127.
Glasheen WP, Renda A, Dong Y. Diabetes complications severity index (DCSI)-update and ICD-10 translation. J Diabetes Complications. 2017;31(6):1007-1013.